Compare Regeneron Pharmaceuticals Inc (REGN) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while 22nd Century Group Inc trades at $4.26 (market cap $1.56M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 45378.2× 22nd Century Group Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| REGN | XXII | |
|---|---|---|
Market Cap | $70.79B | $1.56M |
Sector | Health | Technology |
52-Week High | $812.27 | $999.00 |
52-Week Low | $545.46 | $3.90 |
Enterprise Value | $64.74B | -$6.67M |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
XXII trades at $4.32, down 0.23% on the day, with neutral technical signals and bearish moving averages. The company shows significant financial challenges with negative profit margins (-65.76% net income margin) and declining revenue, though analyst sentiment remains positive with 75% buy ratings. Recent corporate actions include a 20:1 reverse stock split completed in June 2026, while expansion initiatives in California and New York aim to drive VLN brand growth.
The outlook remains speculative with high execution risk given persistent losses and negative ROE (-130.19%). Investment opportunity hinges on successful commercialization of reduced-nicotine products and FDA regulatory progress, but substantial financial deterioration and competitive pressures present significant downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
